Michael Chrobok

Michael Chrobok obtained his Ph.D. in Immunology and Cell Therapy from Karolinska Institutet in 2019, where he engineered genetically modified natural killer (NK) cells and advanced adoptive cell therapy protocols for multiple myeloma. Following his doctoral training, he expanded his scope at Karolinska Institutet’s preGMP facility, coordinating projects that established clinical-grade protocols for modifying primary human T cells. Subsequent roles as a consultant and scientist involved directing quality control assays, conducting validation assays, and integrating manufacturing processes for early-phase (I/II) clinical trials at both academic and industry sites.